Building on the initial support provided by the Department of Hematology at Zhejiang First Hospital, the Department of Hematology has developed over many years and is now a Class I Key Discipline in Jinhua City, a Key Medical Discipline in Yiwu City, and a specialized hematology unit within the National Clinical Drug Trial Base. The department hosts the Academy of Sciences Workstation for Hematological Diseases in Central Zhejiang and has successively become the Central Zhejiang Regional Center of the Provincial Key Scientific and Technological Innovation Team for Leukemia, a member unit of the Chronic Myeloid Leukemia (CML) Charity Assistance Project, a base for the “Beauty of Life” health education project for multiple myeloma patients, and a member unit of the Comprehensive Management Project for Lymphoma Patients. The department currently has two academic leaders, five senior and intermediate-level professionals, and five resident physicians; all clinical physicians hold master’s degrees or higher. The department includes two returning overseas scholars, with staff holding a total of 11 positions as committee members or youth committee members in national and provincial academic organizations. It undertakes provincial and ministerial-level research projects, including grants from the National Natural Science Foundation and public welfare projects from the Department of Science and Technology. Additionally, the department is involved in five international multicenter clinical trials for new drugs and four national multicenter clinical trials for new drugs.
The department possesses strong clinical capabilities, equipped with an independent bone marrow aspiration suite, a cytomorphology laboratory, and advanced equipment such as blood cell separators. It routinely performs MICM testing for hematological diseases and employs advanced immunological, molecular biological, and cytogenetic diagnostic methods to provide precise and standardized diagnosis and treatment for various hematological conditions, including: various blood cell abnormalities, acute and chronic leukemias, malignant lymphomas, multiple myeloma, myeloproliferative neoplasms, myelodysplastic syndromes, and other malignant hematological diseases, as well as bone marrow failure disorders, bleeding and coagulation disorders, and rare blood diseases. The department’s clinical research focuses on the personalized diagnosis and treatment of adult immune thrombocytopenia, personalized diagnosis and treatment of acute leukemia in the elderly, targeted precision therapy for myeloproliferative neoplasms, standardized diagnosis, treatment, and comprehensive management of lymphoma, standardized diagnosis, treatment, and management of multiple myeloma, as well as translational medical research and clinical applications for rare hematological diseases. We employ novel immunotherapy, targeted therapies, modified chemotherapy, and hematopoietic stem cell transplantation, as well as translational medicine approaches. We develop precision treatment strategies guided by molecular stratification, conduct routine disease follow-ups and meticulous management, and possess a prominent regional advantage in the comprehensive diagnosis and treatment of the aforementioned hematological diseases.
Specialized Services
The Hematology Outpatient Clinic is open Monday through Sunday, with specialist clinics held 2–3 times per week.
Various Cytopenias: Anemia, thrombocytopenia, leukopenia, etc.
Hematologic Malignancies: Multiple myeloma, acute and chronic leukemias, lymphomas, etc.
Myelodysplastic Disorders: Myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, myelofibrosis), myelodysplastic syndromes, aplastic anemia, etc.
Hemostatic and Coagulation Disorders: Coagulation disorders, hypofibrinogenemia, hemophilia, etc.
Rare blood disorders: Hairy cell leukemia, POEMS syndrome, Castleman disease, thrombotic thrombocytopenic purpura (TTP), hemophagocytic syndrome, paroxysmal nocturnal hemoglobinuria (PNH), Fanconi anemia, hemophilia, etc.
